Data may compromise the privacy of study participants and may not be shared publicly. Data are available upon request to the authors.

Introduction {#sec005}
============

According to the Ministry of Health and Welfare of Taiwan, since 2006, colorectal cancer (CRC) has become the most common cancer and the third cause of cancer-related death in Taiwan. In 2013, its incidence was 45.1 per 100,000 population, with more than 5,000 deaths per year and an average of 13.1 years of life lost (<http://mohw.gov.tw/CHT/DOS/Index.aspx>; accessed in March 2016). Although surgical resection is the primary treatment modality for CRC, 33%--50% of CRC patients relapse \[[@pone.0163264.ref001]\]. More than 90% of relapses occur during the first 5 years following surgery and at a particularly higher rate in the first 2 years. However, CRC-related deaths are majorly attributable to clinical relapse \[[@pone.0163264.ref001]\]. If the relapse is diagnosed earlier, it may be amenable to resection, leading to a higher rate of resectability and increasing the likelihood of long-term survival \[[@pone.0163264.ref002]\].

Several surveillance strategies for patients undergoing curative primary CRC resection have been reported. Carcinoembryonic antigen (CEA), an oncofetal antigen, is an extensively used disease relapse marker \[[@pone.0163264.ref003]\]; however, the utility of serial CEA testing remains uncertain: in 30%--40% of all CRC recurrences, the serum CEA shows unmeasurable elevations \[[@pone.0163264.ref004]\]. By contrast, transient elevations in CEA levels are observed in patients with resected CRC during adjuvant chemotherapy or immunotherapy. The false-positive rate for elevated serum CEA level detection during follow-up can be as high as 16% \[[@pone.0163264.ref005]\], unnecessarily increasing the difficulty in diagnosing recurrence and increasing patient anxiety \[[@pone.0163264.ref002]\]. Therefore, a more powerful tool for early detection of CRC relapse is required.

Studies for identifying novel panels of multiple molecular and biochemical markers usable for more precisely defining prognosis and predicting of adjuvant treatment benefits in CRC have been reported \[[@pone.0163264.ref006]\]. Reports have described the detection of circulating tumor cells (CTCs) in the peripheral blood of CRC patients; this method has major prognostic and therapeutic implications \[[@pone.0163264.ref007]--[@pone.0163264.ref010]\]. Our recently developed membrane array-based multigene biomarker assay can detect CTCs in the peripheral blood of CRC patients; this is a rational approach for the surveillance of postoperative CRC patients \[[@pone.0163264.ref006],[@pone.0163264.ref011]--[@pone.0163264.ref015]\]. However, a detailed prospective comparative study regarding the diagnostic accuracy of the biomarker chip and serum CEA level detection is required. In the present study, we prospectively analyzed both the biomarker chip and serum CEA level detection periodically after curative resection in Union for International Cancer Control (UICC)/American Joint Committee on Cancer stage I--III CRC patients and identified whether the biochip was more efficient for their postoperative surveillance.

Materials and Methods {#sec006}
=====================

Patients {#sec007}
--------

This prospective study was conducted by a surgical team in a single institution between June 2010 and February 2016. During June 2010 to October 2014, 331 patients were diagnosed with stage I--III CRC. Of these, 33 were excluded: 16 with a \<1-year follow-up before death and 17 with other malignancies. Finally, 298 patients were enrolled after radical curative resection for primary CRC tumor: 82, 102, and 114 stage I, II, and III patients, respectively. The clinicopathological characteristics of these patients are listed in [Table 1](#pone.0163264.t001){ref-type="table"}. The clinical stages and pathological features of the primary tumors were defined according to the seventh edition of the UICC tumor---node---metastasis (TNM) staging system \[[@pone.0163264.ref016]\].

10.1371/journal.pone.0163264.t001

###### Clinicopathological features of 298 colorectal cancer patients.
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  ------------------------------------- -----------------
  Gender (male/female)                  168/130
  Age (year)                            
   Median                               64.21
   Mean ± SD                            64.4±11.3
  Maximum tumor size≧5cm                78 (26.2%)
  Location (rectum/colon)               77/221
  Depth of tumor invasion T (1/2/3/4)   44/67/167/20
  Lymph node metastasis N (0/1/2)       184/74/40
  Histology (WD/MD/PD)                  42/244/12
  TMN stage (I/II/III)                  82/102/114
  Vascular invasion                     86 (28.9%)
  Perineural invasion                   61 (20.5%)
  Abnormal preoperative CEA level       98 (32.9%)
  Abnormal postoperative CEA level      71 (23.8%)
  Postoperative relapse                 48 (16.1%)
  Positive biomarker chip               62 (20.8%)
  Mortality                             26 (8.7%)
  Follow up (month)                     
   Median, range                        28.4, 3.0--61.3
   Mean ± SD                            29.0±9.7
  ------------------------------------- -----------------

Ethics Statement {#sec008}
----------------

The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-950326 & KMUHIRB-2012-03-02(II)). Written informed consent was obtained from the patients, and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The patients also consented to the publication of the clinical details.

Follow-up {#sec009}
---------

According to the clinical practice guidelines recommended by European Society for Medical Oncology Guidelines Working Group \[[@pone.0163264.ref001]\], postoperative surveillance during each follow-up comprised medical history-taking, physical examination, and laboratory studies including serum CEA levels. Abdominal ultrasonography or computed tomography (CT) was performed every 6 months, and chest plain radiography examinations and total colonofiberscopy were performed once a year. Furthermore, elevated CEA levels were defined when two consecutive CEA levels at a 3-month interval of regular follow-up were \>5 ng/mL. In the case of elevated CEA or a positive multigene biomarker chip, high resolution MRI or contrast enhanced CT of the liver was performed before the annual follow-up. Patients were followed every 3 months in the first 3 years and at 6-month intervals thereafter. All patients were followed until death or February 2016. The development of recurrent or metastatic lesions was defined as postoperative relapse.

CTCs in the peripheral blood were detected using our previously constructed multigene biomarker chip with serial CEA assays at each follow-up \[[@pone.0163264.ref007], [@pone.0163264.ref012]--[@pone.0163264.ref015]\]. Additional 4 mL samples of peripheral blood were obtained for total RNA isolation. To prevent contamination by epithelial cells, peripheral blood samples were obtained through a catheter inserted into a peripheral vessel, and the first 5 mL of blood was discarded. Sample acquisition and subsequent use were approved by the institutional review board of the hospital.

Serum CEA Level Detection {#sec010}
-------------------------

Serum CEA levels were determined from additional 3 mL peripheral blood samples by using an enzyme immunoassay test kit (DPC Diagnostic Product Co., Los Angeles, CA, USA), with the upper limit of 5 ng/mL defined as normal, in accordance with the manufacturer instructions.

Gene Selection and Oligonucleotide Design {#sec011}
-----------------------------------------

The authors used a method combining suppression subtractive hybridization and cDNA microarray chips to investigate changes in all genes involved in the carcinogenic pathway from colorectal adenomatous polyps to colorectal cancer \[[@pone.0163264.ref017]\]. 71 genes specific for colorectal cancer as diagnostic markers were successfully identified and the patents were obtained in Taiwan (No. I278519), the USA (No. US 7575928), and the European Union (No. 04 003 301.1). In order to implement the clinical application of specific gene groups, the oligonucleotide sequences of top 19 highly overexpressed target genes of the 71 genes were selected ([Table 2](#pone.0163264.t002){ref-type="table"}), as described previously \[[@pone.0163264.ref018]--[@pone.0163264.ref020]\]; they were designed using the Oligo Explorer software program (Gene Link, Inc. New York, USA).

10.1371/journal.pone.0163264.t002

###### Oligonucleotide sequences of 19 target genes.
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  Gene             oligonucleotide sequences (5\'→ 3\')
  ---------------- ------------------------------------------------------
  PSG2             `CTCGGAAACTTTTGGTGGCTGGGCTTCAATCGTGACTTGGGCAGT`
  ELAVL4           `TTGCCCCTGTTTGCATGGGAGAAGGACAGTTTCTGTTGTTGCTGG`
  TK1              `CAGGGAGAACAGAAACTCAGCAGTGAAAGCCGCAGAGGGGAAGAA`
  UBE2C            `AACTTCACTGTGGGCGCATTGTAAGGGTAGCCACTGGGGAACTCT`
  PDE6D            `TGCCAGAGTATCTTCCCTGTCTCAGCATCCCGAAGGTTCATCCAA`
  PSAT1            `TTGACCTTGAATCAACAGCCGCTGAACCCAGGAGACCCCACAGAT`
  CHRNB1           `TAGGGTCCCAACGCTGGTGAAGATGATGAAAGTCCACAGGAAGAG`
  CEA              `ATCCTGCATCGTTCCTTTTGACGCTGAGTAGAGTGAGGGTCATGT`
  BMI1             `CGAGGTCTATTGGCAAAAGAAGATTGGTGGTTACCGCTGGGGCTG`
  CAP2             `ACATGGCGGAGCCCTTTTGTAATTGCTTCTCCCTGGTTAAGTTGG`
  MMP13            `AAAGTGGCTTTTGCCGGTGTAGGTGTAGATAGGAAACATGAGTGC`
  OLFM4            `AGCAGGTGCCTCATCTACAGATCCTTCTGGGATTTATTTGCCATG`
  PTTG1            `TATCTATGTCACAGCAAACAGGTGGCAATTCAACATCCAGGGTCG`
  MYC              `AGTGACTGTCCAGTTTTGAGAAGCGTCTAGCAAGTCCGAGCGTGTTCAAT`
  MET              `CCCGAGTTCTTTCTATTGATGCGTTCATGCTCTTGACCCTGGTAG`
  MUC1             `CCTGGGGTAGAGCTTGCATGACCAGAACCTGTAACAACTGTAAGCACTGT`
  HMGB1            `ATTGCAGCCTATCACTAACCCTGCTGTTCGCTTGCATGTATCTTG`
  hTERT            `AGGGGTGAACAATGGCGAATCTGGGGATGGACTATTCCTATGTGG`
  BIRC5            `CTCTAACCTGCCATTGGAACCTCACCCATAGCCCAGAAGCCTCAT`
  *Oryza sativa*   `CTCGGTAACCTCTATTCCTCTACACCCTCGACCTCACCAACACCAGCCT`
  *β-actin*        `ATGCTCGCTCCAACCGACTGCTGTCACCTTCACCGTTCCAGTTTT`

Multigene Biomarker Chip Preparation {#sec012}
------------------------------------

The 19 synthesised oligonucleotides were dissolved in distilled water to a concentration of 100 mM and then applied to a BioDOT AD1500 nanoliter dispense system (BioDot, Inc., Irvine, CA, USA), which blotted each oligonucleotide solution sequentially on a Nytran SuperCharge nylon membrane (Schleicher and Schuell, Dassel, Germany) in triplicate. The oligonucleotides were then crosslinked to the membrane by using a UV Stratalinker 1800 (Stratagene, La Jolla, CA, USA). Each spot contained 20 ng of PCR-amplified DNA derived from sequence-verified cDNA clones. DMSO was also dispensed onto the membrane as a blank control.

Detection of Multigene Expression on the Biomarker Chip {#sec013}
-------------------------------------------------------

A GeneCling Enzymatic Gene Chip Detection Kit (CaryGene Biotechnology Co., Ltd., Kaohsiung, Taiwan) was used as follows: Beads first were added for RNA extraction; RT buffer and RT enzyme were then added to synthesize cDNA. Next, Biotin Mix Label was added to the cDNA for biotin-labelling probe synthesis (probe synthesis). The labelled cDNA was then hybridised with the prepared biomarker chip at 42°C for 6--17 h. Wash buffer was then used to wash off the nonhybridized probes, followed by the addition of Streptavidin-AP---NBT/BCIP mixture and incubation at 37°C for a color reaction. Finally, after coloration, the biochips were completely dried, and the software was used to analyze the colorimetric values of the individual genes; these values were translated to indicate the relative intensities of the various gene expressions.

Biomarker Chip Intervention {#sec014}
---------------------------

Subsequent quantification analysis of the intensity of each spot was carried out using AlphaEase^®^ FC software (Alpha Innotech Corp., San Leandro, CA, USA). Spots consistently carrying a factor of two or more were considered to be differentially expressed. A deformable template extracted the gene spots and quantified their expression levels by determining the integrated intensity of each spot after background subtraction ([Fig 1](#pone.0163264.g001){ref-type="fig"}). The fold ratio of each gene was normalized on the basis of the reference gene (β-actin) density, as follows: spot intensity ratio = mean intensity of the target gene/mean intensity of β-actin. [Fig 1](#pone.0163264.g001){ref-type="fig"} provides the schematic representation of the membrane array with 19 candidate genes, one positive control (β-actin), one negative control (Oryza sativa sequence), and the blank control (dd water). If the gene presented a color density \>2-fold higher than the positive control (β-actin) did, the result was defined as positive, whereas if the density was \<2-fold higher than that of the positive control, the result was defined as negative. Each overexpressed spot was then multiplied by the respective weighted values ranging from 1 to 4, according to the principle described previously \[[@pone.0163264.ref018]--[@pone.0163264.ref022]\].

![(A) Schematic representation of the colorectal cancer biomarker chip evacuated using the weighted enzymatic chip array method with the 19 candidate genes, a positive control (β-actin), a negative control (*Oryza sativa*), and a blank control (double distilled water). Oligonucleotide fragments were blotted on the membranes in triplicate, and the expression levels of each gene spot were quantified and then normalized on the basis of the color density of a reference gene (β-actin). (B) Positive biochip result. (C) Negative biochip result.](pone.0163264.g001){#pone.0163264.g001}

ROC Curve and Determination of Cutoff Levels of the Multigene Biomarker Chip {#sec015}
----------------------------------------------------------------------------

The optimal cutoff value of the multigene biomarker chip was determined according to a prior study \[[@pone.0163264.ref018]\]. Receiver operating characteristic (ROC) curve analysis was performed on 557 participants, including 298 CRC patients (not the enrolled patients in the present study) and 259 normal individuals. Based on the calculated cutoff value, the expression of the biomarker chip was defined as either positive or negative. The optimal cutoff value and AUC were 23.5 and 0.980 (95% CI, 0.971--0.989), respectively. When the total score was ≥ 24 by two consecutive analysis, the biomarker chip results were defined as positive.

Data Collection and Statistical Analysis {#sec016}
----------------------------------------

Student *t* and chi-squared tests were used to compare continuous and categorical descriptive variables, respectively, between relapsed and non-relapsed patients. Univariate and multivariate logistic regression analyses were also used to examine the factors influencing the postoperative relapse. The cumulative disease-free survival (DFS) and overall survival (OS) rates were calculated using the Kaplan---Meier method, and the differences in the rates were analyzed using the log-rank test. Results are expressed as the mean with standard deviation or effect and 95% CI where appropriate. A P value of \<0.05 denoted statistical significance. All data were analyzed using SPSS (version 19.0; SPSS, Inc., Chicago, IL, USA).

Results {#sec017}
=======

Descriptive Data {#sec018}
----------------

The median follow-up time was 28.4 months (range, 3.0--61.3 months). Of the 298 patients, 168 were men (56.4%). The average age was 64.4 ± 11.3 years (range, 20--91 years). Regarding tumor histology, 42 (14.1%) were well-differentiated carcinomas, 244 (81.9%) were moderately differentiated, and 12 (4.0%) were poorly differentiated. Forty-eight (16.1%) patients had postoperative relapse and 26 (8.7%) died. Of the 298 CRC patients, 62 (20.8%) had a total biomarker chip score higher than the cutoff value. Of 48 relapsed patients, 42 (87.5%) showed positive biochip results prior to relapse. The positive biochip results were significantly associated with postoperative relapse (P \< 0.001; [Table 3](#pone.0163264.t003){ref-type="table"}). The clinicopathological characteristics of all 298 CRC patients are listed in [Table 1](#pone.0163264.t001){ref-type="table"}. The raw data from the multigene biomarker chip may compromise the privacy of study participants and may not be shared publicly. Data are available upon request to the authors.

10.1371/journal.pone.0163264.t003

###### Comparison between non-relapsed and relapsed colorectal cancer patients.
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                                     Non-relapse N = 250   Relapse N = 48    *P*
  ---------------------------------- --------------------- ----------------- ---------
  Gender (Male/Female)               144/106               24/24             0.331
  Age (year)                         64.2±11.0             65.3±12.8         0.546
  Maximum tumor size≧5cm             66 (26.4%)            12 (25%)          0.840
  Location (rectum/colon)            58/192                19/29             0.018
  Depth of tumor invasion            96/154                15/33             0.348
   T (1+2/3+4)                                                               
  Lymph node metastasis              157/93                27/21             0.392
   N (0/1+2)                                                                 
  Histology (WD+MD/PD)               214/9                 45/3              0.392
  TNM stage (I-II/III)               157/93                27/21             0.392
  Vascular invasion                  68 (27.2%)            18 (37.5%)        0.149
  Perineural invasion                45 (18.0%)            16 (33.3%)        0.016
  Abnormal preoperative CEA level    72 (28.8%)            26 (54.2%)        0.001
  Abnormal postoperative CEA level   42 (16.8%)            29 (60.4%)        \<0.001
  Positive biomarker chip            20 (8.0%)             42 (87.5%)        \<0.001
  Mortality                          6 (1.6%)              20 (29.5%)        \<0.001
  Follow up (month)                                                          
   Median, range                     29.6, 7.3--59.8       24.1, 3.0--61.3   0.058
   Mean ± SD                         29.5±9.5              26.6±10.6         

Univariate and Multivariate Analyses {#sec019}
------------------------------------

During the follow-up period, 29 of 221 (13.1%) colon cancer patients and 19 of 77 (24.7%) rectal cancer patients showed postoperative relapse. In comparison with the patients without postoperative relapse, rectal neoplasms (*P* = 0.018), perineural invasion (*P* = 0.016), elevated preoperative serum CEA levels (*P* = 0.001), elevated postoperative serum CEA levels (*P* \< 0.001), and positive biochip results (*P* \< 0.001) were more frequently noted in the patients with relapse ([Table 4](#pone.0163264.t004){ref-type="table"}). However, sex, age, tumor size, tumor invasion depth, lymph node metastasis, histology, TNM stage, vascular invasion, and follow-up duration did not differ significantly between the studied groups (all *P* \> 0.05).

10.1371/journal.pone.0163264.t004

###### Factors influencing the relapse estimated by univariate and multivariate logistic regression analyses.

![](pone.0163264.t004){#pone.0163264.t004g}

                                     Univariate regression      Multivariate regression                              
  ---------------------------------- -------------------------- ------------------------- -------------------------- ---------
  Maximum tumor size≧5cm             0.929 (0.456, 1.893)       0.840                     \-                         \-
  Location (rectum/colon)            2.169 (1.134, 4.149)       0.019                     1.566 (0.564, 4.348)       0.389
  Depth of tumor invasion            1.371 (0.708, 2.657)       0.349                     \-                         \-
   T (1+2/3+4)                                                                                                       
  Lymph node metastasis              1.313 (0.703, 2.454)       0.393                     \-                         \-
   N (0/1+2)                                                                                                         
  Histology (WD+MD/PD)               1.785 (0.465, 6.851)       0.398                     \-                         \-
  TNM stage (I+II/III)               1.313 (0.703, 2.454)       0.393                     \-                         \-
  Vascular invasion                  1.606 (0.841, 3.068)       0.152                     \-                         \-
  Perineural invasion                2.278 (1.152, 4.502)       0.018                     2.181 (0.716, 6.644)       0.170
  Abnormal preoperative CEA level    2.922 (1.556, 5.488)       0.001                     2.538 (0.885, 7.277)       0.083
  Abnormal postoperative CEA level   7.559 (3.880, 14.724)      \<0.001                   4.136 (1.455, 11.755)      0.008
  Positive biomarker chip            80.500 (30.523, 212.309)   \<0.001                   66.878 (23.229, 192.548)   \<0.001

95% CI: 95% confidence interval

In the multivariate logistic regression analysis, elevated postoperative serum CEA levels (OR = 4.136, 95% CI: 1.455--11.755; *P* = 0.008) and positive biochip results (OR = 66.878, 95% CI: 23.229--192.548; *P* \< 0.001) were revealed to be independent predictors for postoperative relapse ([Table 5](#pone.0163264.t005){ref-type="table"}). However, tumor location (rectum or colon), perineural invasion, and preoperative CEA elevation did not differ significantly between the studied groups (all *P* \> 0.05).

10.1371/journal.pone.0163264.t005

###### Sensitivity, specificity, postitive predictive value, negative predictive value, and accuracy of postoperative serum CEA level and biomarker chip.
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                              Abnormal postoperative CEA level (95% CI)   Positive biomarker chip (95% CI)   *P*
  --------------------------- ------------------------------------------- ---------------------------------- ---------
  Sensitivity                 60.4%                                       87.5%                              0.003
  (45.3%-74.2%)               (74.8%-95.3%)                                                                  
  Specificity                 83.2%                                       92.0%                              0.003
  (78.0%-87.6%)               (87.9%-95.1%)                                                                  
  Positive predictive value   40.8%                                       67.7%                              0.002
  (29.3%-53.2%)               (54.7%-79.1%)                                                                  
  Negative predictive value   91.6%                                       97.5%                              0.006
  (87.2%-94.9%)               (94.6%-99.1%)                                                                  
  Accuracy                    79.5%                                       91.3%                              \<0.001
  (74.9%-84.1%)               (88.1%-94.5%)                                                                  

95% CI: 95% confidence interval

Sensitivities, Specificities, and Accuracies of Postoperative Serum CEA levels and Biomarker Chip for Predicting Postoperative Relapse {#sec020}
--------------------------------------------------------------------------------------------------------------------------------------

Positive biochip results with elevated postoperative serum CEA levels for predicting postoperative relapse were thoroughly compared ([Table 5](#pone.0163264.t005){ref-type="table"}). The biomarker chip demonstrated higher sensitivity (biochip: 87.5%, CEA: 60.4%; *P* = 0.003), specificity (biochip: 92.0%, CEA, 83.2%; *P* = 0.003), positive predictive value (biochip: 67.7%, CEA: 40.8%; *P* = 0.002), negative predictive value (biochip: 97.5%, CEA: 91.6%; *P* = 0.006), and accuracy (biochip: 91.3%, CEA: 79.5%; *P* \< 0.001) than postoperative serum CEA levels did. Therefore, our multigene biomarker chip would be a more accurate tool for predicting postoperative relapse than postoperative serum CEA is.

In clinical practice, the two independent tests can be combined to be more confident of the diagnosis. The combined specificity becomes 1-(1--0.832)×(1--0.92) = 1--0.001344 = 0.998656 = 99.8656%. The combined sensitivity becomes = 0.604×0.875 = 0.5285 = 52.85%. The combined specificity of 99.87% allowed us to rule in the diagnosis: until proved otherwise, this patient had postoperative relapse.

The diagnostic/prognostic values of the biochip and postoperative CEA were evaluated according to different clinical features and shown in [Table 6](#pone.0163264.t006){ref-type="table"}. The positive biochip results showed prominent association with rectal tumor (*P* = 0.009), perineural invasion (*P* = 0.010), postoperative relapse (*P* \< 0.001) and mortality (*P* \< 0.001).

10.1371/journal.pone.0163264.t006

###### Clinical features associated with diagnostic/prognostic values of postoperative CEA and the biochip.
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                            Postoperative CEA (+/-)   Biochip (+/-)   *P*
  ------------------------- ------------------------- --------------- ---------
  Maximum tumor size                                                  0.690
   ≧5cm                     20/58                     15/63           
   \<5cm                    51/169                    47/173          
  Location                                                            0.009
   Rectum                   22/55                     24/53           
   Colon                    49/172                    38/183          
  Depth of tumor invasion                                             0.361
   T (1+2)                  23/88                     20/91           
   T (3+4)                  48/139                    42/145          
  Lymph node metastasis                                               0.934
   N (0)                    42/142                    38/146          
   N (1+2)                  29/85                     24/90           
  Histology                                                           0.069
   WD+MD                    68/218                    57/229          
   PD                       3/9                       5/7             
  TNM stage                                                           0.934
   I+II                     42/142                    38/146          
   III                      29/85                     24/90           
  Vascular invasion                                                   0.328
   Positive                 24/62                     21/65           
   Negative                 47/165                    41/171          
  Perineural invasion                                                 0.010
   Positive                 12/49                     20/41           
   Negative                 59/178                    42/195          
  Postoperative relapse                                               \<0.001
   Yes                      29/19                     42/6            
   No                       42/208                    20/230          
  Mortality                                                           \<0.001
   Yes                      15/11                     19/7            
   No                       56/216                    43/229          

Multigene Biomarker Chip versus Postoperative Serum CEA Levels for Predicting Postoperative Relapse and Clinical Outcomes {#sec021}
-------------------------------------------------------------------------------------------------------------------------

In postoperative surveillance, both multigene biomarker chip analysis and CEA assays were performed at each follow-up. Of the 48 relapsed patients, 42 (87.5%) showed positive biochip results and a median lead time from detection of 10.7 months (11.0 ± 7.3 months; [Table 7](#pone.0163264.t007){ref-type="table"}). However, only 29 (60.4%) relapsed patients had elevated postoperative serum CEA levels, and the median lead time was 2.8 months (3.4 ± 2.8 months). The median lead time between the positive biochip results and subsequent postoperative relapse detection was considerably earlier than that between the elevated postoperative serum CEA levels and postoperative relapse detection (*P* \< 0.001). The median DFS rate was significantly lower among patients with positive biochip results than among patients with negative biochip results (20.4 vs. 48.0 months, *P* \< 0.001; [Fig 2A](#pone.0163264.g002){ref-type="fig"}). The cumulative DFS rate at the end of the study was 95% and 26% for the patients with negative and positive biochip results, respectively. Similarly, the median OS rate was significantly lower among the patients with positive biochip results than among those with negative biochip results (*P* \< 0.001; [Fig 2B](#pone.0163264.g002){ref-type="fig"}). The cumulative proportion OS rate at 48 months was 96% and 51% for those with negative and positive biochip results, respectively.

10.1371/journal.pone.0163264.t007

###### Comparison of the expression prior to the diagnosis in 48 relapsed patients.
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                          Postoperative CEA level   Biomarker chip     *P*
  ----------------------- ------------------------- ------------------ ---------
  Positive result N (%)   29 (60.4)                 42 (87.5)          0.003
  Lead-time (month)                                                    \<0.001
  Median (Range)          2.8 (0.5--11.0)           10.7 (0.5--30.7)   
  Mean ± SD               3.4 ± 2.8                 11.0 ± 7.3         

![(A) Cumulative disease-free survival (DFS) and (B) overall survival (OS) rates of the 298 colorectal cancer patients calculated using the Kaplan---Meier method.\
Positive biochip results correlated strongly with lower DFS and OS rates of colorectal cancer patients (both *P* \< 0.001).](pone.0163264.g002){#pone.0163264.g002}

Discussion {#sec022}
==========

Postoperative surveillance of CRC patients facilitates early diagnosis of disease relapse, which may then be surgically or medically treated. Of the numerous reported follow-up strategies, serial CEA monitoring is the most sensitive for detecting recurrence compared with history-taking, physical examination, liver function tests, abdominal sonography, chest radiography, and colonofiberoscopy; it remains one of the most crucial postoperative work-ups \[[@pone.0163264.ref023]--[@pone.0163264.ref025]\]. In the literature, the estimated sensitivity of serum CEA for detecting relapsed disease in patients with completely resected CRC is 58%--89%, with a 1.5--6.0-month lead time between serum CEA level elevation and recurrence detection \[[@pone.0163264.ref026]--[@pone.0163264.ref029]\]. In the present study, the sensitivity and specificity of elevated serum CEA level detection were 60.4% and 83.2%, with a median lead time of 2.8 months between serum CEA level and relapse detection, consistent with the previous reports. However, the sensitivity and specificity of relapse detection depends largely on the definition of elevated serum CEA levels (cutoff value). The higher the cutoff value for the elevated serum CEA levels is, the higher (lower) the specificity (sensitivity) would be \[[@pone.0163264.ref027], [@pone.0163264.ref030]\].

Elevated preoperative serum CEA levels indicate a poor prognosis and are correlated with a reduced OS after surgical resection \[[@pone.0163264.ref027], [@pone.0163264.ref031]--[@pone.0163264.ref032]\]. In the present study, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of elevated preoperative serum CEA levels for predicting postoperative relapse were 54.1%, 71.2%, 26.5%, 89.0%, and 68.5%, respectively. In addition, the elevated preoperative serum CEA levels were more frequent in patients with relapse than in those without relapse (*P* = 0.001). However, in the multivariate analysis, the postoperative relapse was not associated with elevated preoperative serum CEA levels (*P* = 0.083). Of all clinicopathological features, well known factors, such as depth of invasion and lymph node metastasis, did not affect the recurrence rate in univariate analysis, and the relatively short follow-up period may in part be responsible for it. The elevated postoperative serum CEA levels and positive biochip results were the only two independent predictors of postoperative relapse (P = 0.008 and P \< 0.001, respectively). Of the two independent predictors of relapse, our multigene biomarker biochip was more accurate than postoperative serum CEA levels (91.3% vs. 79.5%, *P* \< 0.001). Moreover, the median lead time between positive biochip results and relapse detection was 10.7 months, considerably earlier than that between elevated postoperative serum CEA levels and relapse detection (2.8 months, *P* \< 0.001). The detection of overexpressed molecular biomarkers on the biochip may facilitate earlier detection of relapsed disease and enable physicians to select early therapeutic strategies.

A weighted enzymatic chip array (WEnCA) platform is a sensitive technique for detecting activated *KRAS* from the peripheral blood in patients with various malignancies \[[@pone.0163264.ref018],[@pone.0163264.ref021],[@pone.0163264.ref022]\]. The selection of the target gene and modification of the weighted values for the corresponding genes contribute the most to the accuracy in clinical applications. To reduce the false-negative detection CTCs when predicting postoperative relapse, cDNA of multiple biomarkers from the peripheral blood were analyzed at each follow-up; the biomarker chips of the CRC patients with subsequent relapse showed that most of the gene spots expressed more prominently with time.

In the present study, the specificity (92.0%) and accuracy (91.3%), but not the sensitivity (87.5%), of the biomarker chip were similar to those reported in previous studies that used the WEnCA platform \[[@pone.0163264.ref018]--[@pone.0163264.ref022]\]. The false-positive rate of the biomarker chip in early prediction of postoperative relapse was 32.3%; nevertheless, postoperative serum CEA levels showed a higher false-positive rate (59.2%). These rates may have been low because of using unadjusted weighted value and limited follow-up period. Therefore, to obtain an acceptable low false-positive rate, individual weighted values of each gene should be further investigated on the WEnCA platform.

Of the 242 patients with negative biochip results, 1 and 4 stage II and III patients relapsed during the follow-up period, respectively. In the biomarker chip of all 5 patients, some gene spots indicating metastatic potential lacked overexpression. Such negative biochip results may be attributable to the histological dedifferentiation or heterogeneity of relapsed tumor or the relapse caused by provocative agents in the environment \[[@pone.0163264.ref033]\].

In the present study, 9, 18, and 21 stage I, II, and III patients demonstrated postoperative relapse (*P* = 0.328) and a median DFS of 21.3, 12.8, and 9.3 months (*P* = 0.081), respectively. The positive predictive value of the biomarker biochip was more favourable than that of postoperative serum CEA levels (67.7% vs. 40.8%, *P* = 0.002). However, of the 62 patients with a positive biomarker biochip result, 5, 7, and 8 stage I, II, and III patients remained relapse-free until the end of the follow-up period, respectively.

In the present study, we confirmed that our constructed multigene biomarker chip is feasible for the accurate early prediction of postoperative relapse in stage I--III CRC patients. The biomarker chip may be used periodically in clinical practice for postoperative surveillance to improve early detection. However, a multicenter trial for CRC patients with a longer follow-up duration is required in order to confirm the long-term effectiveness.

Conflicts of Interest: All authors have read the journal's policy on disclosure of potential conflicts of interest and have none to declare.

[^1]: **Competing Interests:**The corresponding author, Professor Wang, holds a patent in the USA (Genes for diagnosing colorectal cancer: Patent No.: US 7,575,928). However, none of the authors is affiliated with companies, products in development or for market, and/or has any potential for financial gain.

[^2]: **Conceptualization:** JYW TLC.**Data curation:** YTC.**Formal analysis:** HLT.**Funding acquisition:** JYW.**Investigation:** JYW.**Methodology:** MYH.**Project administration:** MYH.**Resources:** JYW.**Software:** YSY.**Supervision:** JYW.**Validation:** CWH.**Visualization:** HLT.**Writing -- original draft:** YTC.**Writing -- review & editing:** JYW TLC.
